CTLA4 and cancer: For instance, M1‐ and M2‐ phenotypes of TAMs display shared mannose/galactose receptors.[187] Similar to T cells, NK cells express several immune checkpoint molecules on their surface (e.g., TIM‐3, CTLA‐4, and PD‐1),[188, 189, 190] along with some intracellular signaling components (i.e., CDk8, Cbl‐b).[191] Thus, nanoformulations targeting these shared components can stimulate undesired immune cell responses in cancer treatment, which might inevitably increase unwanted side effects.